Evidence map›Paper›PMID 27177218›Full record

ReviewBiomaterials2016

Cell-based tissue engineering strategies used in the clinical repair of articular cartilage.

Brian J Huang, Jerry C Hu, Kyriacos A Athanasiou

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Biomaterials, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 159 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
159citing papers in PubMed, 1 pooled it
39.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

159 citing papers in PubMed, 1 synthesis or guideline pooled it, 388 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. 3D-bioprinting for joint regeneration.Frontiers in bioengineering and biotechnology · 2026
    Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article

99 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Brian J HuangDepartment of Biomedical Engineering, University of California Davis, USA. Electronic address: brihuang@ucdavis.edu.
Jerry C HuDepartment of Biomedical Engineering, University of California Davis, USA. Electronic address: jcyhu@ucdavis.edu.
Kyriacos A AthanasiouDepartment of Biomedical Engineering, University of California Davis, USA; Department of Orthopedic Surgery, University of California Davis, USA. Electronic address: athanasiou@ucdavis.edu.
University of California System · USUniversity of California, Davis · US

Funding

Self-assembling process in tissue engineering of articular cartilageR01AR067821 · NIAMS · UNIVERSITY OF CALIFORNIA-IRVINE · PI ATHANASIOU, KYRIACOS A · 2015 to 2019
$1.9M
NIAMS NIH HHS R01 AR067821
6 · The paper itself

Abstract

One of the most important issues facing cartilage tissue engineering is the inability to move technologies into the clinic. Despite the multitude of current research in the field, it is known that 90% of new drugs that advance past animal studies fail clinical trials. The objective of this review is to provide readers with an understanding of the scientific details of tissue engineered cartilage products that have demonstrated a certain level of efficacy in humans, so that newer technologies may be developed upon this foundation. Compared to existing treatments, such as microfracture or autologous chondrocyte implantation, a tissue engineered product can potentially provide more consistent clinical results in forming hyaline repair tissue and in filling the entirety of the defect. The various tissue engineering strategies (e.g., cell expansion, scaffold material, media formulations, biomimetic stimuli, etc.) used in forming these products, as collected from published literature, company websites, and relevant patents, are critically discussed. The authors note that many details about these products remain proprietary, not all information is made public, and that advancements to the products are continuously made. Nevertheless, by understanding the design and production processes of these emerging technologies, one can gain tremendous insight into how to best use them and also how to design the next generation of tissue engineered cartilage products.

Indexed as

Wound HealingAnimalsCartilage, ArticularClinical Trials as TopicHumansTissue EngineeringAutologous chondrocyte implantationCartilage repairCartilage tissue engineeringClinical cartilage productsScaffold-free cartilageScaffolds for cartilage regeneration

Identifiers

PMID27177218
PMCPMC4899115
OpenAlexW2344794523

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.